GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoDyn Inc (OTCPK:CYDY) » Definitions » Shiller PE Ratio

CytoDyn (CytoDyn) Shiller PE Ratio : (As of Apr. 29, 2024)


View and export this data going back to 2005. Start your Free Trial

What is CytoDyn Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


CytoDyn Shiller PE Ratio Historical Data

The historical data trend for CytoDyn's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoDyn Shiller PE Ratio Chart

CytoDyn Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CytoDyn Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CytoDyn's Shiller PE Ratio

For the Biotechnology subindustry, CytoDyn's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CytoDyn's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytoDyn's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where CytoDyn's Shiller PE Ratio falls into.



CytoDyn Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

CytoDyn's E10 for the quarter that ended in Feb. 2024 is calculated as:

For example, CytoDyn's adjusted earnings per share data for the three months ended in Feb. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Feb. 2024 (Change)*Current CPI (Feb. 2024)
=-0.01/129.4194*129.4194
=-0.010

Current CPI (Feb. 2024) = 129.4194.

CytoDyn Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201405 -0.050 100.373 -0.064
201408 -0.060 100.352 -0.077
201411 -0.090 99.635 -0.117
201502 -0.050 99.032 -0.065
201505 -0.240 100.333 -0.310
201508 -0.120 100.548 -0.154
201511 -0.060 100.135 -0.078
201602 -0.050 100.040 -0.065
201605 -0.050 101.355 -0.064
201608 -0.040 101.617 -0.051
201611 -0.040 101.829 -0.051
201702 -0.060 102.779 -0.076
201705 -0.050 103.256 -0.063
201708 -0.080 103.587 -0.100
201711 -0.070 104.072 -0.087
201802 -0.100 105.052 -0.123
201805 -0.040 106.148 -0.049
201808 -0.070 106.383 -0.085
201811 -0.060 106.338 -0.073
201902 -0.040 106.649 -0.049
201905 -0.050 108.048 -0.060
201908 -0.040 108.245 -0.048
201911 -0.040 108.519 -0.048
202002 -0.080 109.139 -0.095
202005 -0.160 108.175 -0.191
202008 -0.060 109.662 -0.071
202011 -0.060 109.793 -0.071
202102 -0.080 110.968 -0.093
202105 -0.110 113.576 -0.125
202108 -0.070 115.421 -0.078
202111 -0.060 117.269 -0.066
202202 -0.060 119.703 -0.065
202205 -0.120 123.323 -0.126
202208 -0.030 124.958 -0.031
202211 -0.030 125.607 -0.031
202302 -0.020 126.928 -0.020
202305 -0.020 128.314 -0.020
202308 -0.010 129.538 -0.010
202311 -0.010 129.548 -0.010
202402 -0.010 129.419 -0.010

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


CytoDyn  (OTCPK:CYDY) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


CytoDyn Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of CytoDyn's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CytoDyn (CytoDyn) Business Description

Traded in Other Exchanges
Address
1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
CytoDyn Inc is a US-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The lead product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
Executives
Tyler Blok officer: EVP of Legal Affairs 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Stephen M Simes director
Ryan Dunlap director 310 N. STATE STREET, SUITE 208, LAKE OSWEGO OR 97034
Arvin Cyrus Arman officer: President 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Karen J Brunke director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Tanya Durkee Urbach director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Lishomwa C Ndhlovu director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Harish Seethamraju director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Alan P Timmins director 1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660
Gordon A Gardiner director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Samir Rashmikant Patel director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Antonio Migliarese officer: Chief Financial Officer 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Chris P Recknor officer: Chief Operating Officer 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Michael D. Mulholland officer: CFO, Treasurer and Secretary 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Jordan G Naydenov director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660

CytoDyn (CytoDyn) Headlines

From GuruFocus

CytoDyn to Hold Webcast to Provide a Quarterly Company Update

By GuruFocusNews GuruFocusNews 06-22-2022

CytoDyn Announces President Takes Medical Leave of Absence

By sperokesalga sperokesalga 05-24-2023